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Aim: We aimed to identify quantitative ultrasound (QUS)-radiomic markers to predict radiotherapy re-
sponse in metastatic lymph nodes of head and neck cancer.Materials & methods: Node-positive head and
neck cancer patients underwent pretreatment QUS imaging of their metastatic lymph nodes. Imaging fea-
tures were extracted using theQUS spectral form, and second-order texture parameters.Machine-learning
classifiers were used for predictive modeling, which included a logistic regression, naive Bayes, and k-
nearest neighbor classifiers. Results: There was a statistically significant difference in the pretreatment
QUS-radiomic parameters between radiological complete responders versus partial responders (p < 0.05).
The univariable model that demonstrated the greatest classification accuracy included: spectral intercept
(SI)-contrast (area under the curve = 0.741). Multivariable models were also computed and showed that
the SI-contrast + SI-homogeneity demonstrated an area under the curve = 0.870. The three-feature model
demonstrated that the spectral slope-correlation + SI-contrast + SI-homogeneity-predicted response with
accuracy of 87.5%. Conclusion: Multivariable QUS-radiomic features of metastatic lymph nodes can pre-
dict treatment response a priori.
Lay abstract: In this study, quantitative ultrasound (QUS) and machine-learning classification was used
to predict treatment outcomes in head and neck cancer patients. Metastatic lymph nodes in the neck
were scanned using conventional frequency ultrasound (US). Quantitative data were collected from the
US-radiofrequency signal a priori. Machine-learning classification models were computed using QUS fea-
tures; these included the linear fit parameters of the power spectrum, and second-order texture parame-
ters of the QUS parametric images. Treatment outcomes were measured based on radiological response.
Patients were classified into binary groups: radiologic complete response (CR) or radiological partial re-
sponse (PR), which was assessed 3 months following treatment. Initial results demonstrate high accuracy
(%Acc = 87.5%) for predicting radiological response. The results of this study suggest that QUS can be
used to predict head and neck cancer response to radiotherapy a priori.
First draft submitted: 15 April 2019; Accepted for publication: 20 September 2019; Published online:
26 November 2019
Keywords: chemoradiation • head and neck carcinoma • predictive assay • quantitative ultrasound • radiation
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Each year, 550,000 head and neck (H&N) cancer cases are diagnosed globally and comprises tumors of the pharynx,
larynx, oral cavity, nasal cavity, paranasal sinuses, and salivary glands [1]. Most H&N tumors arise from epithelial
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cells; thus, squamous cell carcinoma (SCC) accounts for approximately 90% of cases. The risk factors associated
with H&N cancer include tobacco use, alcohol consumption, and human papilloma virus (HPV) infection [2].
There is also evidence to suggest that Epstein–Barr virus is implicated in H&N oncogenesis [3], as well as hereditary
factors, and diseases such as Fanconi anemia [4]. Genetic drivers of H&N cancer have been linked to mutations in
the p53 gene, and deregulation of the PI3K/Akt/mTOR pathway, which are responsible for regulating cell cycling,
survival, and differentiation [2].
Distant metastasis at the time of presentation is rare and accounts for only 10% of patients. Therefore, lo-
coregional treatments are often required to treat the primary tumor and regional lymph nodes [1]. Treatments for
H&N cancer are dependent on the initial staging and may involve surgery, radiotherapy (XRT) or systemic therapy.
XRT is administered as a curative treatment, or as adjuvant therapy, with or without concurrent chemotherapy
(i.e., chemoradiation) depending on the clinical presentation [1]. However, the primary intent is to achieve locore-
gional control (LRC) with long-term disease-free survival [5]. It is estimated that 75% of patients with SCC of the
H&N will derive a benefit from XRT in terms of achieving LRC [6]. Therefore, XRT is frequently used up-front
for curative intent and as part of a multimodality treatment plan [6].
The standard XRT dose is 70 Gy/35 fractions to the gross tumor volume (GTV) and affected lymph nodes,
although different fractionation schemes are also practiced [7,8]. Intensity modulated radiation therapy (IMRT) is
now a technical mainstay and uses inverse planning to achieve steep dose drop-off gradients that result in superior
dose conformality around the target site with minimal dose to normal surrounding tissues [5]. Also, IMRT plans have
benefited greatly from image-guided XRT to correct for anatomical displacements during each treatment fraction,
resulting in superior target localization. Despite these technical and treatment advances, there remains a clinical
problem for a subset of patients who do not respond to treatment; Peng et al. showed that the 5-year mortality
rate was approximately 20% despite patients having received IMRT treatment [9]. Another report indicated that
the annual mortality rates confer 75,000 deaths overall from oral cavity, pharyngeal, and laryngeal malignancies
combined [10]. Taken together, local relapse and death from treatment failure is still a clinical challenge.
To address the clinical challenges associated with aggressive tumors that demonstrate treatment resistance,
response-guided and adaptive XRT have been the focus of intense research. Radiomics-based markers from several
modalities have been investigated recently to measure intratreatment tumor response. The field of radiomics in
oncologic imaging includes characterizing pixel or voxel attributes and their relative spatial relationships within the
image layout. Radiomic data can yield high-dimensional imaging markers and information about tumor biology
(i.e., the imaging phenotype); for example, characterizing hypoxia, intratumor heterogeneity, tissue structure, and
biochemical composition [11–13]. In the context of radiomics-guided therapy, it may provide an opportunity to
adapt and tailor radiation treatments based on physiological information extracted from quantitative imaging
either before or during treatment [14,15].
In previous studies, predictive (a priori) and early-response quantitative ultrasound (QUS) radiomic markers
have demonstrated promising results; for example, measuring breast tumor response to chemotherapy. Sadeghi et al.
reported significant changes in the acoustic backscatter signal as early as 4 weeks after the start of chemotherapy [16].
Recent studies have indicated that texture analyses of QUS-radiomic features can be carried out with multivariate
machine-learning algorithms to predict treatment responses with high accuracy [17,18]. These studies have demon-
strated that QUS-radiomic markers are capable of characterizing tumors in terms of structural properties (i.e., tissue
heterogeneity) and functional attributes; demonstrating a significant correlation to treatment response outcomes.
Here, we report a novel application of QUS spectroscopy to predict treatment response in H&N cancer.
Quantitative radiomic features derived from QUS are computed from the radiofrequency (RF) backscatter signals
that are typically discarded after B-mode image reconstruction. However, in QUS the RF data is retained and
analyzed by applying a Fourier transform to the acoustic backscatter intensity signal, followed by regression
analysis of the frequency-dependent power spectrum. The QUS-radiomic parameters that are determined using
this technique include, the mid-band fit (MBF), 0-MHz intercept (special intercept [SI]) and spectral slope
(SS) [19–22]. Other QUS-radiomic features are also obtained by estimates of the backscatter coefficient, which
relate to tissue microstructure properties (i.e., size and concentration of scatterers) [20,23]. Compared with other
imaging modalities such as positron emission tomography (PET) and MRI, QUS imaging requires only relatively
inexpensive ultrasound (US) technology and does not require contrast agents. Additionally, the major advantages
of QUS compared with conventional gray-scale sonography include independence from user and machine settings.
In this study, we apply these principles within the framework of H&N XRT. Pretreatment, QUS-derived radiomic
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features were obtained from the transformed image of metastatic lymph nodes of 32 H&N cancer patients and we
report radiomic signatures obtained a priori that were associated with XRT treatment response endpoints.
Materials & methods
Patients & treatment
This study was approved by the institutional research ethics board. There were 32 subjects enrolled in this study.
Informed written consent was obtained from all participants. All subjects had a biopsy confirmed diagnosis of
H&N cancer.
As part of the patients’ standard of care, histological analyses of the primary tumor were performed: including
HPV and Epstein–Barr virus [24–26] assays. The patients’ diagnostic workup also included a pretreatment computed
tomography (CT) and MRI scan to obtain radiological information about the initial tumor size and extent
(i.e., primary tumor size, lymph node status, lymph node size, and tumor histological features).
All patients in this study were given chemoradiation or definitive radiation alone (70 Gy over 33 fractions). An
expansion of 5 mm on the GTV was created to form the high-dose clinical target volume on the primary and
nodal volume (70 Gy). Another expansion margin of 1 cm was added to the GTV to create the CTV56 volume.
Elective nodal areas were treated to a dose of 56 Gy. All XRT was administered using modern IMRT or VMAT
techniques [8,27]. A summary of the concomitant systemic therapies used and, radiation treatments are outlined in
Table 1. Patients were selected to ensure neck nodes were sufficiently large and accessible for imaging purposes.
Treatment response evaluation
Treatment response was evaluated from clinical follow-up with radiological assessment using dynamic contrast
enhanced MRI 3 months after completing treatments. Patients were categorized according to their clinical response
into binary classes as either complete responders or partial responders. Patients who were complete responders
demonstrated LRC after XRT, in other words, no residual disease at the primary site or within lymph nodes. In
contrast, patients were classified as partial responders if there was residual disease at the primary site (and/or the
lymph nodes) after the 3-month assessment. Patients who had residual disease after (chemo)radiation were seen for
surgical consideration and salvage.
US data acquisition
The largest lymph node was identified with the guidance of the patient’s treating oncologist. A ‘baseline’ US scan
of the largest involved lymph node was completed for each patient, 2 weeks prior to starting (chemo)radiation, at
the time of CT-planning for XRT.
US data included grayscale (b-mode) images and the digitized RF signal. Data were collected from a commercially
available US device that was customized to retain the RF data (Elekta Ltd, CA, USA). A linear 4D transducer
(4DL14-5/38 Linear 4D, BK Ultrasound, MA, USA) was used for imaging, which had a center frequency of
approximately 8 MHz and a sampling rate of 40 MHz. Data were acquired across the entire lymph node volume,
along 256 lateral scan lines (in-plane; 3.8 cm lateral field of view), with a maximum axial depth of 5 cm. The
acoustic focus was adjusted for the depth of the lymph node for each patient (average depth = 2.5 cm).
QUS feature extraction
QUS analyses were completed using individual RF lines in-plane, within a region-of-interest that was selected
across the entire target lymph node. A sliding window technique was employed with a window block of 2 × 2 mm
and 94% overlap between the adjacent windows in both axial and lateral directions. In order to remove effects of
system transfer functions and beam forming by the transducer, normalization of the spectral form was carried out
by calibrating the signal to the spectra of a tissue-mimicking phantom, with known acoustic properties [28]. Imaging
and measurements were conducted by trained members of a clinical research team. Previous work from the same
research group shows that QUS acquisition by different sonographers and different systems do not significantly
affect the data [29].
An attenuation correction was calculated based on the point-compensation method [30] by estimating the local
attenuation coefficient [31]. There were six QUS parameters computed from the power spectra which included:
MBF, SS, SI, spacing among scatterer (SAS), average scatterer diameter (ASD), and average acoustic concentration
(AAC).
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Table 1. Demographic and clinical information.
Patients characteristics n (%)
Patient and clinical characteristics n = 32 (all subjects)
Age (median) 60 years old
Sex:
– Male
– Female
29 (90.1)
3 (9.4)
Tumor and node status
Primary tumor (T):
– T1
– T2
– T3
– T4
2 (6.3)
23 (71.9)
4 (12.5)
3 (9.4)
Node involvement (N):
– N1
– N2 (all sub-classifications)
– N3
10 (31.3)
20 (62.5)
2 (6.3)
Histological type:
– Squamous cell carcinoma
– EBV(+) nonkeratinizing nasopharyngeal carcinoma
– Small cell carcinoma
30 (93.8)
1 (3.1)
1 (3.1)
HPV status:
– Indeterminate
– p16(+)
– p16(-)
9 (28.1)
22 (68.8)
1 (3.1)
Pretreatment lymph node size (mean, cm ± SD)
Complete responders 2.35 ± 0.66
Partial responders 2.71 ± 0.65
Treatment characteristics
Chemotherapy + radiation (concomitant):
– Cisplatin (high dose)
– Cisplatin (low dose)
– Cisplatin → Carboplatin
– Carboplatin
– Carboplatin + Etoposide
27 (84.4)
23 (71.8)
1 (3.1)
1 (3.1)
1 (3.1)
1 (3.1)
Targeted therapy + radiation (concomitant):
– Cetuximab
1 (3.1)
1 (3.1)
Definitive radiation alone 4 (12.5)
Post-treatment (3-month assessment from magnetic resonance imaging)
Complete response (locoregional control) 13 (40.6)
Partial response (locoregional failure) 19 (59.4)
EBV+: Epstein–Barr virus positive carcinoma; p16+/-: Human papilloma virus (HPV) status (positive/negative); SD: Standard deviation.
The MBF, SS, and SI parameters were derived by applying a linear regression over the normalized power
spectrum within a -6 dB window [32]. The ASD and average acoustic concentration parameters were derived by
fitting a spherical Gaussian model, as well as a fluid-filled sphere model (Anderson model) to the backscatter
coefficient [33,34]. The SAS was derived by applying an autoregressive model on to the power spectrum and using
Burg’s recursive algorithm [35]. For SAS only, determination power spectrum normalization was performed using a
planar reflector reference phantom. The SAS was determined by computing the autocorrelation of the normalized
power spectrum and the frequency at which the peak occurred during the autocorrelation [36–38]. A parametric map
was generated for every QUS-derived radiomic feature.
Texture analysis was completed on QUS parametric maps using a gray-level co-occurrence matrix (GLCM)
algorithm [39]. The GLCM features were calculated from neighboring pixel relationships, based on the relative
pixel-to-pixel distances and gray-level tones [39,40]. Each GLCM was composed of 16 gray-tone values and was
constructed at four inter-pixel distances, within four spatial directions (0, 45, 90, and 135◦). Four textural features
were extracted from each GLCM (Equations 1–4) and were subsequently averaged over all GLCMs for each
parametric image. The four textural features extracted and found to be most useful were contrast (con), correlation
10.2144/fsoa-2019-0048 Future Sci. OA (2019) FSOA433 future science group
Predictive QUS markers in head and neck cancer Research Article
(cor), energy (ene), and homogeneity (hom).
Contrast =
Ng∑
i=1
Ng∑
j=1
(i − j )2 p(i, j ) (Eq. 1)
Correlation =
∑Ng
i=1
∑Ng
j=1 (i ) ( j ) p (i, j ) − μxμy
σxσy
(Eq. 2)
Energy =
Ng∑
i=1
Ng∑
j=1
(p(i, j ))2 (Eq. 3)
Homogeneity =
Ng∑
i=1
Ng∑
j=1
p(i, j )
1 + (i − j )2 (Eq. 4)
For the texture computations, p(i,j) is the probability of having two neighbor pixels with gray-level intensities of
i and j in the map, while Ng is the number of quantized gray-level intensities. The mean and standard deviations are
symbolized as μ and σ , respectively and were calculated for both ith rows and jth columns of the matrix. Contrast
describes the degree of pixel-neighbor contrast probabilities in the image, while correlation describes the linear
dependency between neighboring pixel pairs. The energy measures textural uniformity within neighboring pixels
and homogeneity measures the incidence of pixel pairs at different intensities [39]. A total of 41 radiomic features
were extracted from the QUS data, including spectral parameters and four image texture features calculated from
each spectral parametric map.
Statistical analysis
Each QUS mean value and QUS-texture parameter was averaged over the entire lymph node mass. A Shapiro–Wilk
test was used to test for normality. The differences of means between complete response (CR) and partial response
(PR) groups was determined by either an independent sample t-test for normally distributed data (two-sided, 95%
CI), or a Mann–Whitney U test (two-sided, 95% CI) for datasets that did not exhibit a normal distribution. The
statistical tests were performed on SPSS V.22 (IBM Corporation, NY, USA). A significance level of less than 0.05
was considered significant.
Machine-learning classifiers, including a k-nearest neighbor (k-NN) and a naive-Bayes were used to classify
partial versus complete responders using the QUS parameters. A leave-one-out cross-validation (LOOCV) scheme
at subject level was used to evaluate the performance of the two classifiers. The left-out patient (test sample) in
each iteration remained unseen during classifier parameter tuning (such as k = 1, in k-NN classifier), and feature
selection. Since there were 41 features and only 32 samples, the feature selection within a given model was limited
based on the curse of dimensionality; wherein the number of selected features must be less than the number of
samples in the training set divided by a factor of ten in order to mitigate overfitting [41]. Therefore, a maximum
of three features were selected by the classification models using a sequential forward selection model in a wrapper
framework [42] and by executing a cross-validation on the training set at each fold of the leave-one-out evaluation
scheme. The feature selection method learns which features are most informative at each iteration, choosing the
next features based on already selected features and the internal constraints of the classifier. In order to avoid the
peaking phenomenon due to the curse of dimensionality, ten samples per class were required for each feature
(i.e., 1/10 of the sample set), given there were only 13 samples in the CR class, the best single feature was selected
and used for evaluating the performance of the classifiers. Selection was continued to a maximum of three best
features for this sample population. For each radiomic model, the sensitivity (%Sn), specificity (%Sp), accuracy
(%Acc), and area under the curve (AUC) of the receiver-operating characteristic (ROC) were calculated as the
criteria for the performance of the classifiers. The AUC was calculated based on the prediction for each test sample
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in the leave-one-out cross validation, then pooled and calculated over the entire dataset. CIs were calculated and
reported for predictive models. Machine-learning classification, as well as QUS feature extraction was conducted
on MATLAB-based software (Mathworks, MA, USA). Statistical analysis was conducted for CR (n1 = 13) and PR
(n2 = 19).
Results
Patients & tumor characteristics
Participants in this study had a median age of 60 years (range = 40–82 years old); 29 subjects were male and 3 were
female. There were 13 patients who demonstrated a CR, whereas 19 patients demonstrated a PR. Among the SCC
patients, 22 patients had HPV-positive tumors, one patient had an HPV-negative tumor and seven patients had
indeterminate results. Table 1 summarizes the clinical characteristics of participants.
The mean pretreatment lymph node size was 2.35 ± 0.66 cm for complete responders and 2.71 ± 0.65 cm for
partial responders, which were superficial in depth (i.e., <5 cm from surface) for US examination. Histological
H&N tumor types were primarily SCC (93.8%), Epstein–Barr virus positive nonkeratinizing undifferentiated
nasopharyngeal carcinoma (3.1%), and small cell carcinoma (3.1%). The primary tumor sites included the oral
cavity, oropharynx, hypopharynx, nasopharynx, glottic larynx, supraglottic larynx, and parotid gland.
Treatment details
Treatment characteristics are outlined in Table 1. Concomitant high-dose cisplatin chemotherapy as a radiation
sensitizing agent was given to 23 patients (100 mg/m2; q. 21 days). One patient received low-dose weekly cisplatin
(40 mg/m2; q.1wk) + concomitant XRT. One patient was started on high-dose cisplatin, but later switched to
carboplatin due to severe neuropathy; one patient received two of the three prescribed doses (2/3) of carboplatin
(70 mg/m2/day IV on days 1–4, 22–25 and at days 43–46 of radiation) + concomitant XRT but did not complete
the third cycle of chemotherapy, due to chemotherapy-related toxicity. One patient with small cell carcinoma
received carboplatin AUC 5 IV on day 1; Etoposide 100 mg/m2 IV days 1–3 for q. 21 days + concomitant XRT.
At last, one patient was prescribed cetuximab (initial loading dose of 400 mg/m2 followed by weekly administration
of 250 mg/m2 for 7 weeks) + concomitant XRT. Four patients in the cohort received XRT alone using altered
fractionation with twice-daily radiation, once a week. All patients received 70 Gy in 33 fractions.
QUS-radiomic measurements
Representative magnetic resonance, US B-mode images, and pretreatment lymph node parametric maps are
presented in Figure 1. Figure 1A presents data from a representative patient determined clinically to be a complete
responder. In the clinical MRI data (left panel) there is a diminishment in nodal size to a clinically insufficient
size. Figure 1B presents data from a partial responder with minimal nodal change. Panel sets (A) and (B) also
presents representative QUS parametric images for SS, SI, and ASD (acoustic scatter diameter determined using a
Gaussian fit). As is evident, there are visible differences in the pretreatment parametric images between the complete
responder and partial responder patients with obvious changes in the mean values of parameters.
Figure 2 presents representative data for all QUS-radiomic parameters between complete responders versus
partial responders. This includes parameters which were determined to be statistically, significantly different
and parameters which demonstrated no statistically significant differences between patients that were complete
responders versus partial responders. This data corresponds to Table 2, which presents the significant and near-
significant QUS-mean-values and QUS-textural parameters for the two response groups (i.e., CR vs PR). The
mean QUS parameters did not demonstrate a statistically significant difference between complete responders and
partial responders. However, the MBF demonstrated near significance; the mean MBF value was -1.49 ± 4.06 dB
for complete responders versus -4.70 ± 4.63 dB for partial responders (p = 0.052). Textural analyses demonstrated
both near significant and significant differences between response groups. Near significant features included the
MBF-cor and the SS-con (p = 0.059 and p = 0.061, respectively). Five QUS-GLCM parameters demonstrated a
statistically significant difference between groups: SS-correlation (p = 0.018), SI-contrast (p = 0.022), SI-correlation
(p = 0.018), SI-homogeneity (p = 0.044), and ASD Gaussian correlation (p = 0.031). Overall, the texture-based
features demonstrate greater sensitivity and specificity to detect differences between the response groups (Table 2).
The texture-based parameters that were most effective were related to the contrast and correlation of specific
ultrasound-based parameters.
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Figure 1. Lymph node imaging. (Left panel) representative of T1-weighted MR and (right panel) contoured B-mode
ultrasound images with QUS parametric map overlays of SS, SI, and ASD Gaussian for a complete responder (A) and a
partial responder (B) pre to post treatment. The MR images have been contoured to delineate the lymph node that
was scanned. The displayed QUS-GLCM parameters demonstrated significant differences between complete
responder and partial responder groups in texture analysis. Ultrasound image dimensions are: axial distance (image
height) 4 cm, lateral distance (horizontal length) 6 cm. Scale bar = 2 cm (ultrasound image).
ASD: Average scatterer diameter; GLCM: Gray-level co-occurrence matrix; MRI: Magnetic resonance imaging; QUS:
Quantitative ultrasound; SI: Special intercept; SS: Spectral slope.
Table 2. Mean quantitative ultrasound values and mean quantitative ultrasound gray-level co-occurrence matrix feature
values for complete responders and partial responders.
Parameter (Units) Mean value (CR) Mean value (PR) p-value
MBF (dB) -1.49 ± 4.06 -4.70 ± 4.63 0.052
MBF-cor (AU) 0.91 ± 0.26 0.93 ± 0.02 0.059
SS-con (AU) 1.84 ± 0.43 1.57 ± 0.33 0.061
SS-cor (AU) 0.81 ± 0.03 0.84 ± 0.03 0.018
SI-con (AU) 1.86 ± 0.36 1.57 ± 0.36 0.022
SI-cor (AU) 0.81 ± 0.02 0.84 ± 0.04 0.018
SI-hom (AU) 0.70 ± 0.02 0.71 ± 0.03 0.044
ASD (gau)-cor (AU) 0.80 ± 0.03 0.83 ± 0.03 0.031
AAC (and) (dB/cm3) 101.23 ± 3.78 98.19 ± 4.58 0.058
Reported values are mean ± one standard error of the mean. Bold parameters demonstrate statistical significance between groups. Other features approached near significance.
AAC: Average acoustic concentration; ASD: Average scatterer diameter; AU: Arbitrary unit; CR: Complete response; dB: Decibel; MBF: Mid-band fit; PR: Partial response; QUS: Quantitative
ultrasound; SI: Special intercept; SS: Spectral slope.
In order to understand which parameters were best for the a priori prediction of treatment response, machine-
learning approaches were undertaken to evaluate the predictive capabilities of single and multiple parameters
in combination. Classification methods were compared and specifically ROC were computed to evaluate the
performance of QUS parameter(s) using a logistic regression classifier, naive-Bayes classifier, and then a k-NN
approach. Table 3 presents results using a logistic regression classifier for univariate, 2-feature, and 3-feature
models. The univariate feature sensitivity ranged between 61 and 69% and specificity ranged between 63 and
68%. Univariate results showed that the SI-cor demonstrated the lowest predictive performance with a sensitivity
of 61.5% and a specificity of 63.2% (AUC = 0.682). In contrast, the best univariate feature using the logistic
regression classification method was the SI-con, which demonstrated a sensitivity of 61.5%, specificity of 68.4%
and AUC = 0.741. Logistic regression analyses for combination features showed that the combination using three
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Figure 2. Scatter plots of the quantitative ultrasound mean-value and textural parameters for complete responders and partial
responders at pretreatment. Error bars represent ± one standard error of the mean.
*p < 0.05.
AAC: Average acoustic concentration; ASD: Average scatterer diameter; SAS: Spacing among scatterer; SI: Special intercept; SS: Spectral
slope.
Table 3. Results for the best univariate (A), bivariate (B) and multivariate (C) features using a logistic regression classifier.
Predictive QUS radiomic models from univariate and multivariate feature sets
A: Univariate feature model %Sn %Sp AUC
– SS-cor 69.2 68.4 0.737
– SI-con 61.5 68.4 0.741
– SI-cor 61.5 63.2 0.682
– SI-hom 61.5 63.2 0.713
– ASD (gau)-cor 61.5 63.2 0.704
– MBF 61.5 63.2 0.688
B: 2-feature multivariate model %Sn %Sp AUC %Acc
– SI-con + SI-hom 76.9 78.9 0.870 84.4
– SI-con + ASD (gau)-cor 69.2 68.4 0.740 71.9
C: 3-feature multivariate model %Sn %Sp AUC %Acc
– SI-con + SI-hom + MBF 76.9 78.9 0.879 84.4
– SS-cor + SI-con + SI-hom 84.6 84.2 0.911 87.5
Bold fields represent the best performing feature within the feature set.
Acc: Accuracy; ASD: Average scatterer diameter; AUC: Area under the curve; MBF: Mid-band fit; QUS: Quantitative ultrasound; SI: Special intercept; Sn: Sensitivity; Sp: Specificity; SS:
Spectral slope.
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Figure 2. Scatter plots of the quantitative ultrasound mean-value and textural parameters for complete responders and partial
responders at pretreatment (cont.). Error bars represent ± one standard error of the mean.
*p < 0.05.
AAC: Average acoustic concentration; ASD: Average scatterer diameter; SAS: Spacing among scatterer; SI: Special intercept; SS: Spectral
slope.
features, in other words, SS-correlation + SI-contrast + SI-homogeneity, resulted in the highest classification
performance (Sn = 85%, Sp = 84% and AUC = 0.91).
Table 4 presents the results of cross-validated classifications of complete and partial responders in advance
of treatment using the naive-Bayes and k-NN classifiers for a single feature, two features, and three features.
The numbers below the AUC in parentheses show the 95% CI. The corresponding ROC curves for naive-
Bayes and k-NN classifiers for one, two, and three features are presented in Figure 3. Naive-Bayes classification
performed best for univariate and two-feature set; whereas, k-NN classification was better for classifying CR/PR
using a three-feature model. For a single-feature model, an accuracy of 91.5% was achieved by the SS-contrast
(%Sn = 85.8%, %Sp = 97.3% and AUC = 0.866) using the naive-Bayes classifier for baseline data. Using two
QUS and texture features (i.e., MBF+ SS-con), the classification performance showed a sensitivity of 80.4%, a
specificity of 93.9% and an AUC of 0.848 (%Acc = 87%). The k-NN classifier for three features had an accuracy of
83.3%, which corresponded to an AUC of 0.859 using the following parameters: MBF-cor + MBF-hom + SS-con.
Figure 4 presents the naive-Bayes and k-NN feature space for QUS parameters wherein the respective axes are the
selected features of that model with each sample distributed in space. The red and green areas of the two-feature
classification are the decision boundaries for response. The k-NN analyses for univariate feature sets corresponded
with an accuracy of 77.1% (MBF homogeneity parameter; Sn = 71%, %Sp = 83.5% and AUC = 0.810). Also, the
k-NN classifier performed better as the number of features was increased from one to two features; the %Sn, %Sp
and AUC for two features were 78.5%, 83.5% and 0.845, respectively. All classification values for naive-Bayes and
k-NN classification models are summarized in Table 4.
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Figure 3. Results of univariable, two-feature and three-feature classification models using naive Bayes and
k-nearest neighbor classifiers. Models with the greatest AUC values are presented.
AAC: Average acoustic concentration; AUC: Area under the curve; k-NN: k-nearest neighbor; MBF: Mid-band fit; PR:
Partial response; SS: Spectral slope.
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Table 4. Results for the best univariable (A), bivariable (B) and multivariable (C) features with machine-learning
algorithms, k-nearest neighbor and naive-Bayes.
Machine learning classification using QUS radiomic features
A: Univariate models
Classifier %Sn %Sp AUC (95% CI) %Acc Univariate Model
– naive-Bayes 85.8 97.3 0.866 (0.73,1.01) 91.5† SS-con
– k-NN 71.0 83.5 0.810 (0.64, 0.98) 77.1 MBF-hom
B: 2-feature classification
Classifier %Sn %Sp AUC (95% CI) %Acc 2-feature multivariable
model
– naive-Bayes 80.4 93.9 0.848 (0.70, 1.00) 87.1† MBF + SS-con
– k-NN 78.5 83.5 0.845 (0.69, 1.00) 81.0 AAC (and) + MBF-hom
C: 3-feature classification
Classifier %Sn %Sp AUC (95% CI) %Acc 3-feature multivariable
model
– naive-Bayes 72.3 84.6 0.766 (0.59, 0.94) 78.5† MBF + MBF-hom + SS-con
– k-NN 77.7 88.9 0.859 (0.71, 1.00) 83.3 MBF-cor +
MBF-hom + SS-con
†Note that the decrease in classification performance using the naive Bayes classifier from univariate to multivariable models is due to a peaking phenomenon. For this model, the best
classification was based on a univariate feature set.
AAC: Average acoustic concentration; %Acc: Accuracy percentage; AUC: Area under the curve; k-NN: k-nearest neighbor; MBF: Mid-band fit; QUS: Quantitative ultrasound; Sn: Sensitivity;
Sp: Specificity; SS: Spectral slope.
Discussion
In this study, we report that the pretreatment QUS-radiomic signatures obtained in metastatic H&N lymph nodes
taken a priori are predictive of clinical treatment endpoints. This first clinical report for QUS in H&N cancers
demonstrates that using both uniparameter and multiparametric QUS-radiomic markers from texture analyses can
be used to differentiate complete responders from partial responders up-front. There are significant differences in
the texture-based parameters related to SS, SI, and ASD parametric images. The results of this study suggest that
metastatic lymph nodes demonstrate imaging phenotypes that correspond to the treatment responses of primary
H&N cancer tumors.
Radiomic markers for treatment response in H&N cancer have been studied previously; for example,
PET [14,15,43]. Lehtio¨ et al. reported that the pretreatment tumor blood flow parameters from PET imaging
were associated with response outcomes [43]. In that study, high blood flow markers were linked to poor local
control after XRT [43]; while subjects that demonstrated a higher fractional hypoxic volume also had worse survival
outcomes (p = 0.036) [43]. More recent studies using PET to measure pretreatment and early hypoxia in HPV+
H&N cancer have been useful for biomarker-guided XRT [15]. Other studies have investigated quantitative MRI to
monitor XRT response; Cao et al. reported techniques in dynamic contrast enhanced MRI to measure alterations
in tumor blood volume (BV) and blood flow before and after 2 weeks of starting XRT [44]. The results showed
a significant increase in the BV for patients who had locally controlled disease; whereas, patients who had local
failure had an insignificant change in the BV [44].
Other MRI techniques, such as diffusion-weighted MRI measure the apparent diffusion coefficient; a study by
King et al. purported a significantly lower apparent diffusion coefficient, as measured after 2 weeks of XRT, for
patients who had local treatment failure [45]. Another use of radiomics in H&N cancer was also to differentiate
between benign and malignant lymph nodes, and to characterize cervical lymphadenopathy using dynamic sus-
ceptibility contrast MRI [46,47]. Indeed, these studies represent a significant effort to identify markers at early time
intervals, since early detection can potentially inform response-guided XRT, avoid ineffective treatment regimens,
and avert unnecessary side effects. Two recent studies in H&N cancer also used machine-learning to predict clinical
outcome. Vallie˙res et al. used radiomic features from the PET-CT data and clinical features of 300 H&N cancer
patients to predict locoregional recurrence and distant metastases with an AUC of 0.69 and 0.86, respectively [48].
Leger et al. compared the performance of 11 machine-learning algorithms and 12 feature selection methods to find
an optimal prediction model of locoregional tumor control using CT data [49]. Although these previous studies
hold great promise, the major limitations for MRI- and PET-CT based radiomic tests include high equipment
and imaging costs, limited portability of these systems and radiation exposure, as is the case for PET imaging.
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Figure 4. Multivariable feature spaces for datasets using naive Bayes and k-nearest neighbor classifiers. (A) Two-feature classification
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Representative three-feature classification showing the relative spatial boundaries between CR versus PR samples. Feature axes have been
normalized.
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Spectral slope.
QUS is poised to address some of these limitations, with the capability of probing tissue microstructure and
characterizing malignancies based on their acoustic properties; thus, providing information about tissue and tumor
composition [50]. The information can serve also to identify tumor and tissue phenotypes that are susceptible or
resistant to radiation damage.
It is well-known that a tumor’s biological composition is implicated in radiation response. The tumor stroma is
a complex microenvironment and is constituted by a matrix of abnormal cell types, biomolecules, and immature
vasculature [51,52]. Canonical radiobiology has established tumor cells as the primary targets from radiation injury;
however there is also evidence to suggest that radiation damage to vascular endothelial cells mediates tumor cell
death [53]. The tortuous vasculature and poor diffusion of biomolecules causes hypoxia, which is implicated in
radiation resistance [54]. The disorganized microenvironment creates spatial heterogeneities which have effects on
tissue microstructure and organization; thus, forming a progressive disorganized structure as tumors become more
aggressive. This disorganization of the tumor is in principle detectable by QUS [55]. Early QUS studies have
shown that there is a relationship between the acoustic backscatter signal and tissue properties [23,56,57]. Scatterers
and nonscattering medium that constitute tissue in principle, such as cells and interstitial fluid can modulate US
signals [56]. Lizzi et al. framework demonstrated that the scatters’ size (diameter), effective concentration, and the
acoustic impedance (CQ2) contributes to properties of spectral data [56].
Indeed, in this present study, QUS imaging involved adjacent metastatic lymph nodes and the driving hypothesis
was that the biological features in the infiltrated lymph nodes correlated to responses of the primary tumor and nodal
disease. Previous studies, which have shown promising results, have used this hypothesis to guide their studies [58,59].
Hauser et al. reported pretreatment MRI-based parameters, such as the f-value obtained from diffusion-weighted
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imaging in metastatic H&N lymph nodes, were predictive of LRC and failure from XRT [58]. In that study, the
mean initial f-value, which is representative of the vascular and perfusion signal, was greater in patients who had
locoregional failure (LRF) versus those that had LRC (p = 0.01) [58]. Earlier studies using needle probes to measure
oxygen have demonstrated that the pretreatment oxygen content in metastatic lymph nodes were predictive of tumor
response to XRT [59,60]. In those studies, low oxygenation, as measured by the pO2, were reported as a statistically
significant (p = 0.01) predictor of LRF [59,60]. Although this current study does not directly measure the functional
and physiological parameters associated with vascularity and hypoxia, the QUS-radiomic parameters represent the
tissue’s biophysical structure. The results of the study here, are consistent with those previous reports, in terms
of linking the pretreatment tissue parameters with predicting treatment response. The importance of evaluating
metastatic lymph nodes for measuring the likelihood of LRF and as a prognostic indicator after (chemo)radiation
is well-recognized [61]. Multiple regression analyses by Goguen et al. reported that positive lymph nodes after
chemoradiation showed decreased overall survival (p < 0.001) and progression-free survival (p = 0.01) [62]. Chen
et al. conducted a retrospective study in 117 H&N patients who received adjuvant chemoradiation [63]. There
was an improvement in the 3-year local failure free survival (i.e., no evidence of recurrence) in patients with fewer
metastatic lymph nodes at the time of neck dissection [63]. Results of those studies suggest that the presence of
malignant lymph nodes may also represent more aggressive disease [64].
The performances of radiomic biomarkers to predict XRT response may surpass known clinical predictors, such
as tumor (T) and nodal (N) extent [65]. Previous studies have shown that advanced H&N cancer that demonstrate
larger tumors (T2–T4) have a greater likelihood of local failure by ≥50%, compared with early-stage disease with
smaller tumors (T1) [66]. Similarly, the rate of complete XRT response in N2 disease was found to be 41%, compared
with patients with N2 disease (response rate = 64%) [67]. In univariate logistic regression models, the relative risk
(RR) of achieving a complete response to XRT was, RR = 10 for tumor extent (p = 0.005); whereas, using nodal
involvement in the univariate model portended a RR = 4.2 (p = 0.037) [67]. Other predictive clinicobiological
factors include increased radiosensitivity in HPV+ patients [68,69]. Significant improvements in LRC following
XRT were observed in patients who expressed HPV-related markers, such as p16. The hazard ratio (HR) for LRC
was HR = 0.32 (p < 0.0001) between HPV+ and HPV- patients [68].
Medical imaging will continue to play a critical role in oncology and emerging radiomic techniques will be at the
forefront of advancing personalized medicine. The potential applications for QUS-based radiomic markers, when
information is acquired before treatment, will be an opportunity to evaluate tumor phenotypes so that clinicians and
patients can make more informed treatment decisions. The benefits of response-predictive assays include avoiding
ineffective treatments and its related side effects, potentially attaining better LRC through tailored therapies and
ultimately, predictive radiomic assays hold the promise of achieving better survival end points. Patients predicted
up-front not to respond to two Gy fractionation to a total dose of 70 Gy could be offered altered fractionation or
stereotactic radiosurgery or radiation enhancing treatments in order to improve outcomes.
The main limitations of this study include a small sample size and not all lymph nodes in the H&N were
evaluated in subjects due to depth penetration. Tissue heterogeneity between lesions may have been present; for
example, nine patients did not have information on HPV (p16) status as these patients received their diagnostic
work from outside institutions. Future work may involve subgroup analyses for patients with HPV-, SCC since
these patients have been shown to have worse survival outcomes [70]. Despite these limitations, the results here are
promising and warrant further research with a greater sample sizes and with a longer follow-up period to measure
patient outcomes.
Conclusion
In this study, we present first results of QUS-radiomic markers as a response-predictive assay in H&N cancer
XRT. There were statistically significant differences in QUS-radiomic parameters between complete responders
versus partial responders, which included the SS-correlation, SI-contrast, SI-correlation, SI-homogeneity, and
ASD-correlation. QUS-radiomic features used in multiparametric models demonstrated a high level of accuracy in
classifying patients as complete responders versus partial responders after completing (chemo)XRT; thus, pretreat-
ment QUS-radiomic features obtained from metastatic lymph nodes demonstrated an association to XRT response
in the primary tumor.
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Future perspective
Radiomics-guided XRT has the promise of personalizing treatments for patients with H&N cancer. The advantage
of using QUS-based biomarkers include noninvasive imaging, cost–effectiveness and portability of equipment.
Imaging biomarkers from QUS can yield information that reflects the biology and physiology of tumors and
is poised to provide greater clinical insight, such as measuring treatment efficacy and tumor aggressiveness. In
doing so, treatments may be tailored for each patient. Artificial intelligence plays an important role in these
developments; research groups are incorporating machine-learning techniques to discern optimal prediction and
response models, with encouraging results. Preliminary outcomes in developing these techniques warrants further
work to include larger sample groups, incorporate clinical markers such as tumor size and specifically for H&N
cancer, and other predictors of XRT response such as HPV status. Future work may include exploring multimodal
response models wherein biospecimen-based biomarkers are combined with imaging features. Overall, identifying
response to therapy in cancer patients with the use of imaging and machine-learning techniques is a promising
avenue toward precision medicine.
Summary points
Background & purpose
• Despite advances in image-guided radiotherapy (XRT) for head and neck (H&N) cancer, local relapse and death
from treatment failure remains a challenge.
• Quantitative ultrasound (QUS) radiomic markers in metastatic lymph nodes of H&N cancer patients were
investigated as a priori predictive markers for response to (chemo)XRT.
Patients & methods
• Thirty-two patients with diagnosed node-positive H&N cancer receiving standard-dose XRT for cure underwent
QUS spectroscopy imaging of metastatic lymph nodes.
• Second-order statistical analyses using a gray-level co-occurrence matrix followed by machine-learning methods
using logistic regression, naive-Bayes and k-nearest neighbor classifiers, determined best parameters for
predicting patients’ clinical response.
Results
• There were significant differences in QUS-radiomic parameters between complete responders and partial
responders, which included the spectral slope-correlation, spectral intercept (SI)-contrast, SI-correlation,
SI-homogeneity and the average scatterer diameter-correlation (p < 0.05).
• The best performing univariate and bivariate features were SI-contrast (area under the curve = 0.741) and
SI-con + SI-hom (area under the curve = 0.870), respectively.
• The highest accuracy (87.5%) in a priori treatment response prediction was achieved by the combined parameter,
spectral slope-cor + SI-con + SI-hom.
Conclusion
• Pretreatment multivariate QUS-radiomic features obtained from metastatic lymph nodes can predict a priori
between partial and complete response to XRT in the primary tumor.
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